Cargando…

PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology

SIMPLE SUMMARY: Atherosclerosis is a critical cardiovascular disease associated with the use of immune checkpoint inhibitors (ICIs). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key orchestrator of atherosclerotic process and it is also involved in cancer progression and immune-resista...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quagliariello, Vincenzo, Bisceglia, Irma, Berretta, Massimiliano, Iovine, Martina, Canale, Maria Laura, Maurea, Carlo, Giordano, Vienna, Paccone, Andrea, Inno, Alessandro, Maurea, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000232/ https://www.ncbi.nlm.nih.gov/pubmed/36900189 http://dx.doi.org/10.3390/cancers15051397

Ejemplares similares

SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients
por: Quagliariello, Vincenzo, et al.
Publicado: (2020)

Combination of Spirulina platensis, Ganoderma lucidum and Moringa oleifera Improves Cardiac Functions and Reduces Pro-Inflammatory Biomarkers in Preclinical Models of Short-Term Doxorubicin-Mediated Cardiotoxicity: New Frontiers in Cardioncology?
por: Quagliariello, Vincenzo, et al.
Publicado: (2022)

Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
por: Quagliariello, Vincenzo, et al.
Publicado: (2022)

Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
por: Quagliariello, Vincenzo, et al.
Publicado: (2023)

Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression
por: Quagliariello, Vincenzo, et al.
Publicado: (2021)

The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
por: Quagliariello, Vincenzo, et al.
Publicado: (2021)

Resveratrol in Cancer Patients: From Bench to Bedside
por: Berretta, Massimiliano, et al.
Publicado: (2020)

Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models
por: Quagliariello, Vincenzo, et al.
Publicado: (2020)

Multiple Effects of Ascorbic Acid against Chronic Diseases: Updated Evidence from Preclinical and Clinical Studies
por: Berretta, Massimiliano, et al.
Publicado: (2020)

Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome
por: Fabiani, Iacopo, et al.
Publicado: (2020)

NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells
por: Quagliariello, Vincenzo, et al.
Publicado: (2020)

Women at heart: Introducing gender cardio-oncology
por: Canale, Maria Laura, et al.
Publicado: (2022)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology
por: Canale, Maria Laura, et al.
Publicado: (2022)

Corrigendum: Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals
por: Bisceglia, Irma, et al.
Publicado: (2023)

Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals
por: Bisceglia, Irma, et al.
Publicado: (2023)

ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO)
por: Bisceglia, Irma, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?
por: Modena, Alessandra, et al.
Publicado: (2016)

The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies
por: Berretta, Massimiliano, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients
por: Inno, Alessandro, et al.
Publicado: (2021)

Circulating Vitamin D Level and Its Impact on Mortality and Recurrence in Stage III Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Ozone Exerts Cytoprotective and Anti-Inflammatory Effects in Cardiomyocytes and Skin Fibroblasts after Incubation with Doxorubicin
por: Simonetti, V., et al.
Publicado: (2019)

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
por: Vafaei, Somayeh, et al.
Publicado: (2022)

Nano-Encapsulation of Coenzyme Q10 in Secondary and Tertiary Nano-Emulsions for Enhanced Cardioprotection and Hepatoprotection in Human Cardiomyocytes and Hepatocytes During Exposure to Anthracyclines and Trastuzumab
por: Quagliariello, Vincenzo, et al.
Publicado: (2020)

Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy
por: Canale, Maria Laura, et al.
Publicado: (2020)

Improved Survival and Quality of Life Through an Integrative, Multidisciplinary Oncological Approach: Pathophysiological Analysis of Four Clinical Cancer Cases and Review of the Literature
por: Berretta, M., et al.
Publicado: (2022)

Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story
por: Bisceglia, Irma, et al.
Publicado: (2022)

Corrigendum: Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story
por: Bisceglia, Irma, et al.
Publicado: (2022)

Corrigendum: Cardio-oncology in the COVID Era (Co & Co): The never-ending story
por: Bisceglia, Irma, et al.
Publicado: (2023)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary
por: Tarantini, Luigi, et al.
Publicado: (2017)

Cardiac toxicity of chemotherapy for breast cancer: do angiotensin-converting enzyme inhibitors and beta blockers protect?
por: Bisceglia, Irma, et al.
Publicado: (2023)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

PCSK9 inhibitors in the prevention of cardiovascular disease
por: Latimer, James, et al.
Publicado: (2016)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
por: Péč, Martin Jozef, et al.
Publicado: (2023)

Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment
por: El-Osta, Hazem, et al.
Publicado: (2016)

Resveratrol as Chemosensitizer Agent: State of Art and Future Perspectives
por: Cocetta, Veronica, et al.
Publicado: (2021)

Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
por: Riccio, Gennaro, et al.
Publicado: (2016)

Statement for Appropriate Clinical Use of PCSK9 Inhibitors
por: Nohara, Atsushi, et al.
Publicado: (2018)

Just Price for PCSK9 Inhibitors: No less, No More
por: Nasir, Khurram
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i5su21d72b9kll8jpcfrm7mvkk